tradingkey.logo

Neogenomics Inc

NEO
查看详细走势图
11.420USD
+0.150+1.33%
收盘 02/06, 16:00美东报价延迟15分钟
1.47B总市值
亏损市盈率 TTM

Neogenomics Inc

11.420
+0.150+1.33%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.33%

5天

-5.31%

1月

-10.78%

6月

+108.01%

今年开始到现在

-2.89%

1年

-15.34%

查看详细走势图

TradingKey Neogenomics Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Neogenomics Inc当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗服务供应商行业排名29/75位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价13.50。中期看,股价处于平稳状态。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Neogenomics Inc评分

相关信息

行业排名
29 / 75
全市场排名
159 / 4521
所属行业
医疗服务供应商

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Neogenomics Inc亮点

亮点风险
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
业绩高增长
公司营业收入稳步增长,连续3年增长29.59%
估值高估
公司最新PE估值-12.87,处于3年历史高位
机构减仓
最新机构持股134.68M股,环比减少5.47%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值434.19K

分析师目标

根据 13 位分析师
持有
评级
13.500
目标均价
+19.79%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Neogenomics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Neogenomics Inc简介

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
公司代码NEO
公司Neogenomics Inc
CEOZook (Antony P)
网址https://neogenomics.com/
KeyAI